Prediction of lymphovascular invasion in invasive breast cancer based on clinical-MRI radiomics features

Abstract

Objective

We aim to develop a predictive model for lymphovascular invasion (LVI) in patients with invasive breast cancer (IBC), using magnetic resonance imaging (MRI)-based radiomics features.

Methods

A total of 204 patients with IBC admitted to our hospital were included in this retrospective study. The data was split into training and validation sets at a 7:3 ratio. Feature normalization was conducted, followed by feature selection using ANOVA, correlation analysis, and LASSO in the training set. The final step involved building a logistic regression model. The LVI prediction models were established by single sequence image and combined different sequence images as follows: A: prediction model based on the optimal sequence in the 7-phase enhanced MRI scans; B: prediction model based on the optimal sequences in the sequences T1WI, T2WI, and DWI; and C: the combined model based on the optimal sequences selected from A and B. Subjects' work characteristic curves (ROC) and decision curves (DCA) were plotted to determine the extent to which they predicted LVI performance in the training and validation sets. Simultaneously, nomogram models were constructed by integrating radiomics features and independent risk factors. In addition, an additional 16 patients from the center between January and August 2024 were collected as the Nomogram external validation set. The ROC and DCA were used to evaluate the performance of the model.

Results

In the enhanced images, Model A built based on the enhanced 2-phase achieved the best average AUC, with a validation set of 0.764. Model B built based on the T2WI had better results, with a validation set of 0.693. Model C built by combining enhanced 2-phase and T2WI sequences had a mean AUC of 0.705 in the validation set. In addition, the tumor size, whether the tumor boundary was clear or not, and whether there was a coelom in the tumor tissue had a statistically significant effect on the LVI of IBC, and a clinical-radiomics nomogram was established. DCAs as well as Nomogram also indicate that Model A has good clinical utility. The AUC of the nomogram in the training set, internal validation set, and external validation set were 0.703, 0.615, and 0.609, respectively. The DCA also showed that the radiomics nomogram combined with clinical factors had good predictive ability for LVI.

Conclusion

In IBC, MRI radiomics can serve as a noninvasive predictor of LVI. The clinical-MRI radiomics model, as an efficient visual prognostic tool, shows promise in forecasting LVI. This highlights the significant potential of pre-radiomics prediction in enhancing treatment strategies.